Hetero Healthcare Ltd is supplying 60,000 vials of Covifor, generic variant of Remdesivir shot in the country in July 13 to 20, '' the company website said.

Covifor is your first generic variant of Remdesivir, which is supposed for treatment of COVID-19 patients who are adults and kids, hospitalised with severe signs of the disorder.

The medication is available at 100 mg vial (Injectable). It needs to be administered in a hospital, critical care setting, under the oversight of a registered medical practitioner.

Out of 60,000 vials, Maharashtra, which gets the maximum quantity of COVID-19 cases while in the country will probably get 12,500 followed by Delhi along with Telangana with 10,000 and 9,000 respectively.

The company has supplied the medication as much as 166 hospitals in Maharashtra and 5-3 from the national capital.

When it concerns Telangana, Hetero supplied 14,502 vials, the information available at 11 am on the webpage on Wednesday said.

Remdesivir is the only drug approved by the United States Food and Drug Administration (USFDA) for Emergency Usage Authorisation (EUA) treatment of adult and paediatric patients hospitalised with suspected or lab confirmed COVID-19 disease.

Meanwhile, Dr Reddy's Laboratories Ltd, which likewise has a non-exclusive licensing agreement with Gilead Sciences Inc to enroll, manufacture and sell the investigational medication, Remdesivir from 127 countries including India is yet to have a nod from the DCGI to start making the drug in the country, sources said.